The past two weeks have been packed with diabetes tech news, and our biggest highlight came from Tandem. We got a first look demo of Tandem’s FDA-cleared 7-day infusion set on this week’s podcast. That episode dives into updates on the upcoming tubeless Mobi and answers to your questions straight from Tandem.
Beyond pumps, we rounded up the top CGM developments you should know about and broke down Beta Bionics’ Mint tubeless patch pump in a new explainer video. Plus, we spoke with an expert about why diabetes tech innovation often moves more slowly than expected—and the work underway to speed it up. Let’s get to it!
5 Upcoming CGM Upgrades You Need to Know About
The world of CGMs is advancing fast. Dexcom is releasing a 15-day G7 and Abbott is developing a dual glucose-ketone sensor. Meanwhile Medtronic and Senseonics are bringing their own major updates too. Here are the five CGM upgrades you need to keep on your radar.
Our recent news stories:
If you want to read this newsletter later, open it in a browser:
Interview With Tandem: Exclusive 7-Day Set Demo & Tubeless Mobi Preview
Tandem Diabetes came on the podcast to give us a live demo its FDA cleared 7-day infusion set. We hear directly from Tandem’s Senior Product Director about recent safety warnings, the upcoming tubeless Mobi option, and when those outside the US can expect to get their hands on the tech. The episode also dives into future device releases and the next-generation Control IQ Plus algorithm. Plus, I asked them your questions!
Beta Bionics Patch Pump – What We Know So Far
Beta Bionics is bringing its iLet algorithm to a patch pump. The upcoming Mint promises a simple, phone-free site-change with reusable hardware and disposable pods that carry up to 200 units of insulin. It’s still a few years out, but Mint is slated to hit the market in 2027. To break it all down, I put together an explainer video covering what we know so far, images and video of the device, and why it could be a game-changer.
Why Diabetes Tech Innovation Is Slow & The Work To Speed It Up
On our recent podcast we spoke with Shannon Lantzy, a former NASA and FDA expert, about why pumps and CGM upgrades take so long to develop, the inner workings of the FDA, and how current political and regulatory pressures are shaping device approvals. We also explore the diabetes community’s efforts to create universal standards that could safely speed up innovation. Click below to hear the full conversation and hear how medical technology gets cleared.
I joined Neil Gatehouse on his podcast Your Best T1D Year to talk about my Tik Tok diagnosis story and where diabetes tech is headed. We cut through the dual-hormone hype, highlight why the Tandem Mobi bolus button is a game-changer, dive into AI for unannounced meals, and look at why the future is probably tubeless with one device doing it all. Listen to the episode to hear my take on what’s next in diabetes tech. This was one of the most fun podcast interviews, thanks Neil!
Want more?
If you’re finding value in our content—consider joining Diabetech All Access, our premium membership for the most engaged members of our community.
All Access unlocks exclusive stories, Live Q&As (beginning October), and industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving. Thank you for your continued support!